In this episode, you’ll learn how to use the Atherogenic Index of Plasma (AIP) in prediabetes and type 2 diabetes to help prevent major heart events. The article includes an easy-to-use AIP calculator so you can enter your lab numbers and understand what they may mean.
🎧 ▶️ Press the play button below to listen in English.
🇨🇳 中文（简体）
在这一期里，我们会用通俗的方式讲清楚：在糖尿病前期和2型糖尿病中，如何使用血浆动脉粥样硬化指数（AIP）来帮助预防重大心血管事件。文章里还附有一个简单好用的AIP计算器，你只要输入化验单上的数值就能立刻算出结果并理解它的意义。
请按下方的播放按钮收听。
🇪🇸 Spanish (Latinoamérica)
En este episodio, aprenderás cómo usar el Índice Aterogénico del Plasma (AIP) en la prediabetes y la diabetes tipo 2 para ayudar a prevenir eventos cardíacos mayores. En el artículo encontrarás una calculadora de AIP fácil de usar para ingresar tus resultados de laboratorio y entender qué pueden significar.
Presiona el botón de reproducir para escuchar.
I. Why AIP matters in Pediabetes and Type 2 diabetes
A lot of people assume heart risk is simple:
- High LDL = high risk
- Normal LDL = low risk
But in prediabetes and type 2 diabetes, cardiovascular risk often rises for a different reason: insulin resistance quietly reshapes the “triglyceride–HDL pattern” long before (or alongside) obvious diabetes complications.
It’s common to see triglycerides creep up and HDL drift down, even when LDL doesn’t look alarming. That pattern can signal a more atherogenic metabolic environment.
This article is built around a large peer-reviewed study you may see cited online: “Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus” by Fu and colleagues. (published in Cardiovascular Diabetology).
In that analysis, researchers used data from the ACCORD program and evaluated 10,251 people with type 2 diabetes, tracking major adverse cardiovascular events (MACE) over follow-up.
We’ll use that study to explain AIP (Atherogenic Index of Plasma)—a simple number calculated from triglycerides and HDL—and then extend the concept to prediabetes, where the same metabolic pattern often begins years earlier.
II. Prediabetes is the “early chapter” of the same story as type 2 diabetes
Prediabetes isn’t a harmless label—it’s often the stage where insulin resistance has already taken hold, but blood sugar hasn’t crossed the diagnostic line yet.
In everyday terms, it means your body is starting to struggle to handle glucose efficiently, and that struggle tends to echo through the rest of the metabolism.
Clinically, common cutoffs include:
- A1c 5.7%–6.4% (prediabetes range), and
- Fasting glucose 100–125 mg/dL (prediabetes range).
Why bring this up in an article anchored to a type 2 diabetes cardiovascular outcomes study? Because prediabetes and type 2 diabetes often share the same upstream driver—insulin resistance—and insulin resistance commonly shifts lipids in a recognizable way:
- Triglycerides creep up
- HDL (“good cholesterol”) drifts down
That’s the exact metabolic fingerprint that AIP captures (it’s built from TG and HDL). So while the study we’re using followed people with established type 2 diabetes, the pattern it highlights frequently begins earlier—during prediabetes—when prevention can be most powerful.
III. What is ASCVD—and why prevention matters most in prediabetes and type 2 diabetes
ASCVD stands for atherosclerotic cardiovascular disease—conditions caused by plaque buildup in artery walls.
The American Heart Association describes ASCVD as plaque-driven disease and ties it to multiple clinical conditions (like coronary disease and stroke).
Plaque buildup (atherosclerosis) is not an overnight event. It’s a gradual process where fatty deposits accumulate and narrow arteries, reducing blood flow and raising the risk of heart attack or stroke.
This matters even more in prediabetes and type 2 diabetes because insulin resistance tends to cluster risk factors together—blood sugar dysregulation, lipid changes, inflammation, and often higher blood pressure.
The point of checking markers like AIP is not to panic or chase numbers—it’s to spot a risk pattern early enough to change the trajectory.
Think of it this way:
- Treatment is what you do after the disease declares itself.
- Prevention is what you do when the warning lights are already blinking.
AIP is one of those potential warning lights—especially when TG and HDL are moving in the wrong direction.
IV. Meet AIP: a simple number that captures a prediabetes-style lipid pattern
AIP (Atherogenic Index of Plasma) is a calculated marker based on two routine lab values: triglycerides (TG) and HDL cholesterol (HDL-C).
In the ACCORD/ACCORDION analysis we’re using as our anchor study, AIP is defined as a logarithmically transformed ratio of TG to HDL-C in molar concentration (mmol/L)—in other words:
AIP = log(TG / HDL-C) (with TG and HDL-C in mmol/L).
Why would anyone care about a TG/HDL-based number?
Because in both prediabetes and type 2 diabetes, insulin resistance commonly nudges lipids in the same direction:
- TG tends to rise
- HDL tends to fall
That “TG up / HDL down” pattern is one of the most common metabolic fingerprints of insulin resistance—and AIP turns it into a single value.
The authors also summarize why AIP has attracted attention in research:
- It has been reported as a sensitive marker of lipoprotein profiles, and it can help predict lipoprotein particle size, which correlates with cardiovascular risk.
- It can provide information on the severity of insulin resistance, which is directly related to impaired glucose metabolism. Atherogenic index of plasma is …
Practical warning (so you don’t get the wrong number): Many U.S. labs report TG and HDL in mg/dL, but the AIP definition above uses mmol/L.
The AIP calculator in this article accepts both mg/dL and mmol/L—just select the unit that matches your lab report.
V. What the ACCORD/ACCORDION study found—and why it should make prediabetics pay attention
The study titled “Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus” performed a secondary analysis of the ACCORD/ACCORDION data.
The authors explain that 10,251 people with type 2 diabetes were recruited from 77 sites across North America (January 2001 to October 2005) and followed through the post-trial observation period.
What outcome were they tracking?
Their primary outcome was MACE (major adverse cardiovascular events), defined as:
- nonfatal myocardial infarction (heart attack)
- nonfatal stroke
- and/or death from cardiovascular causes
The key result readers should remember
After analyzing AIP values in this large T2DM cohort, the researchers reported:
- The optimal AIP cut-off for predicting MACE was 0.34.
- People with AIP > 0.34 had a significantly higher risk of developing MACE than those in the lower-AIP group.
- They note that AIP showed greater prognostic power for cardiovascular deaths and nonfatal heart attacks.
They also provide details showing the direction and magnitude of risk differences between high vs low AIP groups for specific events (univariable results), including higher rates of cardiovascular death and nonfatal MI in the high-AIP group.
A practical “why this matters even before diabetes.”
The study population had type 2 diabetes, so we shouldn’t pretend the same cutoff automatically applies to everyone with prediabetes. But the logic is highly relevant to prediabetes:
- The authors point out that LDL-C isn’t always the most informative marker in diabetes, and they describe AIP as a log TG/HDL measure that reflects glucose-lipid metabolism and can be independent of LDL-C.
- Prediabetes is often the earlier stage where this TG-HDL shift begins. So AIP can act like a metabolic “signal flare” that something is moving in the wrong direction—before someone is diagnosed with type 2 diabetes or before they’ve had a cardiovascular event.
Subgroup note (especially relevant for women)
In their prespecified subgroup table, the high-AIP vs low-AIP association with MACE was stronger in women than in men (female HR 1.566 vs male HR 1.230 as presented in the table).
VI. Extending AIP to prediabetes: why this marker can matter before diabetes
The ACCORD/ACCORDION analysis we’re using followed people with type 2 diabetes—so it gives us strong evidence that AIP tracks cardiovascular outcomes in a high-risk group. But the reason AIP is so relevant to prediabetes is simpler: prediabetes is often the early stage of insulin resistance, and insulin resistance commonly shows up as the same lipid pattern AIP captures—higher triglycerides with lower HDL.
In other words, AIP can function like an early “metabolic smoke alarm.” It doesn’t diagnose plaque, and it doesn’t replace standard risk assessment. But it can flag a TG–HDL pattern that often travels with insulin resistance and cardiometabolic risk.
Who should consider checking AIP (especially if your goal is ASCVD prevention)?
- Anyone with prediabetes-range labs (A1c 5.7–6.4% or fasting glucose 100–125 mg/dL).
- People told they have “borderline” triglycerides, “low HDL,” fatty liver, belly fat, or metabolic syndrome features.
- Anyone with a strong family history of early heart attack/stroke, even if LDL looks “okay.”
How to use it (without overreacting)
- Treat AIP as a conversation starter and a motivation tool.
- If your AIP is high, the next move isn’t panic—it’s addressing the basics that shift TG and HDL in the right direction (we’ll cover that later), and considering other risk markers with your clinician.
VII. How to calculate AIP correctly (and avoid the #1 mistake)
Step 1: Get the two lab numbers
You need:
- Triglycerides (TG)
- HDL cholesterol (HDL-C)
A fasting sample is often preferred because triglycerides can rise after meals (and AIP is TG-sensitive).
Step 2: Plug you Triglyceride and HDL numbers below. Make sure you choose the right units
Atherogenic Index (AIP) Calculator
Calculates AIP = log10(Triglycerides ÷ HDL) using mmol/L internally.
Interpreting the number (keep it sensible)
The paper notes commonly cited general-population bands:
- AIP < 0.11 (lower risk)
- 0.11–0.21 (intermediate)
- > 0.21 (higher)
But it also explains that people with type 2 diabetes tend to have higher AIP, and in this ACCORD/ACCORDION analysis, the optimal cut-off for MACE prediction was 0.34.
Understand what the diabetes outcomes study adds
In the ACCORD/ACCORDION analysis of people with type 2 diabetes, the authors report an optimal AIP cut-off of 0.34 for predicting MACE in that population.
That does not mean:
- Everyone with an AIP above 0.34 will have an event, or
- everyone below 0.34 is “safe,” or
- That 0.34 is the perfect cutoff for prediabetes.
What it does mean is that in a large, high-risk T2DM cohort, higher AIP tracked with higher event risk—so it’s a number worth paying attention to, especially if you’re in the prediabetes → diabetes pathway and want to prevent ASCVD.
Practical interpretation for readers
- Low AIP: TG/HDL pattern is generally favorable.
- Borderline to high AIP: suggests a more atherogenic pattern often linked to insulin resistance.
- If AIP is high but LDL is “normal”: that’s exactly the scenario where AIP can add insight—because the TG/HDL pattern may be showing risk biology that LDL alone doesn’t capture.
What to do with the information
Use AIP as a reason to look at the whole picture, not as a standalone verdict. Consider tracking (with your clinician as needed):
- Non-HDL cholesterol and/or ApoB (better reflects atherogenic particle burden)
- Blood pressure
- A1c / fasting glucose
- Waist circumference, fatty liver, and other insulin-resistance clues
VIII. How to lower AIP (and reduce ASCVD risk) — the high-yield moves
Because AIP is driven by triglycerides and HDL, the most effective approach is to improve the metabolic “upstream” issues that push TG up and HDL down—especially insulin resistance.
1) Cut the biggest TG drivers first
- Reduce added sugar and refined starches (sweet drinks, pastries, white bread, candy, frequent snacks).
- If you’re prediabetic, pay special attention to “healthy-looking” sugar sources that still spike TG over time (sweetened yogurt, fruit juice, sweet coffee drinks).
2) Address visceral fat (even modest loss helps)
Losing even a modest amount of abdominal/visceral fat tends to improve insulin resistance, often lowering TG and improving HDL over time.
3) Move daily — then add training that changes metabolism
- Walking after meals (simple and surprisingly effective for glucose and TG handling).
- Resistance training (muscle improves glucose disposal and insulin sensitivity).
- Aerobic exercise (improves metabolic flexibility and triglyceride clearance).
4) Watch alcohol if TG is high
Alcohol can significantly raise triglycerides in many people. If your TG is elevated, reducing alcohol can be one of the fastest ways to improve the TG side of AIP.
5) Sleep and stress: not “soft,” but metabolic
Short sleep and chronic stress hormones contribute to insulin resistance. Improving sleep consistency and stress-management habits can make the other changes work better.
6) When to involve a clinician sooner
Talk to your clinician promptly if:
- triglycerides are very high (especially if ≥500 mg/dL due to pancreatitis risk),
- You have multiple risk factors (hypertension, smoking, strong family history),
- or you have symptoms (chest pressure, exertional shortness of breath, neurologic symptoms).
Medication decisions (statins, TG-lowering therapy, diabetes/prediabetes treatment) should be individualized, but AIP can be a useful prompt for a deeper prevention discussion.
Key Takeaways
Prediabetes and type 2 diabetes often share the same upstream driver: insulin resistance, which commonly raises triglycerides and lowers HDL.
AIP (Atherogenic Index of Plasma) captures this TG–HDL pattern as a single number: log(TG/HDL) in mmol/L.
In a large type 2 diabetes outcomes analysis from ACCORD/ACCORDION (10,251 participants), a higher AIP tracked with a higher risk of MACE, and an optimal cut-off around 0.34 separated higher vs lower risk groups in that population.
AIP is not a diagnosis, but it can be an early warning marker—especially for people with prediabetes who want to prevent ASCVD.
The best way to lower AIP is to improve insulin resistance: cut sugar/refined carbs, lose visceral fat, exercise (especially resistance + aerobic), limit alcohol if TG is high, and prioritize sleep.
Frequently Asked Questions
1) What do I need to calculate AIP?
You only need two numbers from your lipid panel: triglycerides (TG) and HDL cholesterol (HDL-C). AIP is defined as the log of TG/HDL-C in mmol/L.
2) Do I need a fasting lipid panel for AIP?
Fasting is often preferred because triglycerides can rise after meals, and AIP is very TG-sensitive.
Many guidelines discuss triglycerides using fasting and nonfasting thresholds and define fasting TG elevation as ≥150 mg/dL (mild–moderate) and≥500 mg/dL (severe).
If you only have a nonfasting lipid panel, you can still calculate AIP—but consider repeating fasting labs if TG is elevated.
3) Is AIP the same thing as the TG/HDL ratio?
They are related, but not the same.
TG/HDL ratio is a simple ratio.
AIP is a logarithmically transformed TG/HDL measure (in mmol/L).
AIP compresses the range and is commonly used in research as a standalone index.
4) Can my LDL be “normal” but my AIP be high?
Yes. In the ACCORD/ACCORDION analysis, the authors note that LDL-C may not reliably distinguish prognosis in diabetes, and they describe AIP as reflecting glucose-lipid metabolism and being independent of LDL-C.
That’s one reason AIP can add insight in prediabetes and type 2 diabetes, where TG tends to rise and HDL tends to fall.
5) What AIP number should worry me if I have prediabetes?
Be careful with rigid cutoffs. The ACCORD/ACCORDION paper studied type 2 diabetes, and in that population, they found an optimal AIP threshold of 0.34 to separate higher vs lower MACE risk groups.
For prediabetes, it’s more appropriate to use AIP as a trend and pattern marker, and to interpret it alongside your full risk profile (blood pressure, A1c, waist size, family history, etc.).
The diagnostic ranges for prediabetes (A1c 5.7–6.4% and fasting glucose 100–125 mg/dL) are defined by the CDC.
6) If my AIP is high, does that mean I’m going to have a heart attack?
No. AIP is not a diagnosis and does not predict a specific event for an individual. The ACCORD/ACCORDION analysis shows that, in a large cohort of people with type 2 diabetes, higher AIP was associated with higher rates of MACE during follow-up.
Think of it as a risk signal that should prompt prevention actions—not as a sentence.
7) What if my triglycerides are very high—should I still focus on AIP?
If fasting triglycerides are ≥500 mg/dL, that’s considered severe hypertriglyceridemia and is treated as a pancreatitis risk zone in major guidance documents.
In that situation, the priority is working with a clinician to rapidly lower triglycerides (dietary changes, addressing secondary causes, and medication when appropriate), and AIP becomes secondary to immediate risk management.
8) How often should I recheck AIP?
A practical approach is to recheck whenever you would reasonably recheck TG and HDL: after a focused lifestyle change period (often 8–12 weeks is common in practice), or at routine intervals recommended by your clinician for cardiometabolic monitoring.
Because AIP is derived from TG and HDL, it will change as those change. (The study by Fu and colleagues used repeated follow-up over years, emphasizing long-term risk tracking in diabetes.)
9) Does AIP matter more for women?
In the paper’s prespecified subgroup analysis, the hazard ratio linking high vs low AIP to MACE was higher in women than in men (as reported in their subgroup table).
That doesn’t mean AIP “only matters” for women—just that, in this dataset, the association appeared stronger.
10) Should I measure ApoB (or non-HDL) instead of AIP?
They answer different questions.
ApoB/non-HDL better reflects atherogenic particle burden (how many LDL-family particles are circulating).
AIP reflects a metabolic lipid pattern tied to TG and HDL.
For prevention, many people benefit from knowing both particle burden (ApoB/non-HDL) and metabolic pattern (AIP), interpreted with your clinician.
Don’t Get Sick!
Medically Reviewed by Dr. Jesse Santiano, MD
Dr. Santiano is a retired internist and emergency physician with extensive clinical experience in metabolic health, cardiovascular prevention, and lifestyle medicine. He reviews all medical content on this site to ensure accuracy, clarity, and safe application for readers. This article is for educational purposes and is not a substitute for personal medical care.
💡 Support This Work
Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.
🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!
Follow me on Facebook, Gab, Twitter (formerly known as X), and Telegram.
Related:
- Stay Strong, Live Long: Creatine And Exercise Builds Muscles
- Activity Snacks Supercharge Muscle Growth And Heart Health Fast
- Alzheimer’s Risk Starts Earlier Than You Think — Here’s How to Stop It
- Protein Requirement Calculator for Adults
- From Helpless To Hopeful: How Exercise Restores Your Life
- Overcome Chronic Depression With Exercise, Healing Body And Mind
- Break Free From Sitting—Reclaim Energy And Life
- Disuse Syndrome: The Hidden Path to Self-Induced Frailty—and How to Reverse It
- Heart Rate Recovery Reveals Hidden Secrets About Your Heart
- Unlock Your Target Heart Rate Without A Monitor
- Is It Really Okay to Be Overweight? New Danish BMI–Mortality Study Explained
- Free BMI Calculator: Unlock Your Body’s Health Code Now
- High BMI: A Silent Killer Shortening Your Life
- A New Definition Of Obesity Is Making Medicine Better
- The Hidden Connection Between Hyperinsulinemia, Obesity, Inflammation, and Cancer
References:
- Fu, Liyao, et al. “Atherogenic Index of Plasma Is Associated with Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus.” Cardiovascular Diabetology, vol. 20, 2021, article 201. https://doi.org/10.1186/s12933-021-01393-5
- Centers for Disease Control and Prevention. “Diabetes Testing.” CDC, 15 May 2024.
- American Heart Association. “Atherosclerotic Cardiovascular Disease (ASCVD).” American Heart Association.
- American Heart Association. “What Is Atherosclerosis?” American Heart Association, 16 Feb. 2024.
- Dobiásová, Mária, and Jiri Frohlich. “The Plasma Parameter log(TG/HDL-C) as an Atherogenic Index: Correlation with Lipoprotein Particle Size and Esterification Rate in ApoB-Lipoprotein-Depleted Plasma (FERHDL).” Clinical Biochemistry, 2001. PubMed. https://pubmed.ncbi.nlm.nih.gov/11738396/
- Centers for Disease Control and Prevention. “Diabetes Testing.” CDC, 15 May 2024.
- American Heart Association. “What Is Cardiovascular Disease?” American Heart Association, 10 Jan. 2024.
Disclaimer:
This article is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions based on the TyG Index or other biomarkers.
© 2018 – 2025 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment
As an Amazon Associate, I earn from qualifying purchases
Discover more from Don't Get Sick!
Subscribe to get the latest posts sent to your email.